Malignant Haematology
Leukaemia, lymphoma, myeloma, and myeloproliferative conditions — diagnostic criteria, staging, and treatment frameworks aligned to ELN, BSH, and NICE.
AML — Diagnosis & Risk Stratification
WHO 2022 classification, ELN 2022 risk categories, and frontline treatment pathways including intensive and non-intensive options.
CML — Diagnosis, Monitoring & TKI Selection
BCR-ABL1 monitoring milestones, ELN response criteria, TKI choice, and management of treatment resistance or intolerance.
Myeloma — Diagnosis, Staging & Response
IMWG diagnostic criteria, R-ISS staging, MRD assessment, and response evaluation in transplant-eligible and non-eligible patients.
DLBCL — Classification & Management
WHO 2022 lymphoma classification, IPI risk stratification, R-CHOP-based regimens, and CNS prophylaxis criteria.
CLL — Unified ELN / BSH / ASH Guideline
MBL distinction, iwCLL active disease criteria, Binet/Rai staging, FISH + TP53 + IGHV work-up, first-line treatment (zanubrutinib TA931, acalabrutinib TA689, venetoclax+obi TA1119), R/R management, Richter's transformation, and infection prophylaxis. BSH 2025 · NICE aligned · v1.9 April 2026.
MDS — Diagnosis & Risk Stratification
WHO 2022 classification, IPSS-R scoring, treatment pathway including ESAs, hypomethylating agents, and transplant eligibility.
General Haematology
Anaemia, haemoglobinopathies, cytopenias, and haematological emergencies — grounded in NICE and BSH guidance for everyday clinical decision-making.
Anaemia in Pregnancy — UK Clinical Guideline
Trimester Hb thresholds, ferritin interpretation, oral iron first-line, IV iron indications & safety, postpartum Hb bands, and transfusion principles. Four pathway diagrams, one-page bedside summary, teaching deck, patient leaflet and audit workbook. BSH 2020 · NICE · RCOG · MHRA · NHS SCT. v1.0 April 2026.
Anaemia — Investigation & Management
Diagnostic pathway covering iron deficiency, B12/folate deficiency, haemolytic anaemia, and anaemia of chronic disease including investigation algorithm.
Neutropenic Sepsis — Assessment & Treatment
Febrile neutropenia risk stratification using MASCC score, empirical antibiotic pathways, escalation criteria, and antifungal considerations.
Sickle Cell Disease — Acute & Long-Term Care
Management of acute crisis, acute chest syndrome, and chronic complications. Hydroxyurea indications, transfusion thresholds, and newborn screening.
Thrombocytopenia — Differential & Approach
Structured diagnostic approach to low platelet counts, distinguishing ITP, hypersplenism, marrow failure, HIT, and TTP/HUS.
Aplastic Anaemia — Diagnosis & Management
Severity criteria (SAA/vSAA), bone marrow transplant eligibility, IST with ATG/cyclosporin, and eltrombopag use in the current era.
Thalassaemia — Classification & Monitoring
Alpha and beta thalassaemia genotypes, transfusion dependency criteria, iron chelation regimens, and transplant/gene therapy indications.
Haemostasis & Thrombosis
Venous and arterial thrombosis, bleeding disorders, and coagulopathies — from anticoagulation management to inherited bleeding conditions.
Cancer-Associated Thrombosis — VTE Management
Anticoagulant selection (DOAC vs LMWH), Khorana risk stratification, duration of therapy, recurrent VTE, and thromboprophylaxis decisions in active malignancy.
ITP in Adults — Diagnosis & Management
Diagnosis of exclusion, when to treat vs observe, first-line corticosteroids/IVIG, TPO-RA therapy (NICE TA221/TA853), splenectomy, and emergency bleeding management.
TTP — Recognition & Emergency Treatment
PLASMIC score, ADAMTS13 testing, plasma exchange, caplacizumab, rituximab, and monitoring for relapse in acquired TTP.
HIT — Diagnosis & Anticoagulation
4T score, HIT antibody testing, heparin cessation, and alternative anticoagulant selection (argatroban, fondaparinux, DOACs).
Haemophilia — Factor Replacement & Prophylaxis
Severity classification, prophylaxis regimens, extended half-life factors, emicizumab, inhibitor management, and perioperative cover.
Antiphospholipid Syndrome
Revised Sapporo classification, antibody testing interpretation, anticoagulation in thrombotic APS, and obstetric APS management.
Transfusion Medicine
Blood component use, patient blood management, transfusion reactions, and special situations — including transfusion support in haematological malignancy.
Red Cell Transfusion — Thresholds & Consent
Restrictive vs liberal transfusion strategies, Hb thresholds by clinical context, pre-transfusion sampling, and patient consent requirements.
Platelet Transfusion — Indications & Thresholds
Prophylactic and therapeutic thresholds for platelets in bleeding, procedures, and haematological malignancy. Irradiated and HLA-matched components.
Massive Haemorrhage Protocol
MHP activation criteria, ratio-based resuscitation (RBC:FFP:platelets), viscoelastic testing (ROTEM/TEG), TXA use, and cell salvage.
Patient Blood Management
Pre-operative optimisation, iron infusion protocols, intraoperative blood conservation, and post-operative anaemia management aligned to NHS PBM programme.
Transfusion Reactions — Recognition & Management
Classification of acute and delayed reactions, immediate management of TACO, TRALI, acute haemolytic reactions, and SHOT reporting pathway.
Transfusion in Haematological Malignancy
Indications for irradiated and CMV-negative components, chronic transfusion support in MDS and aplasia, and iron overload monitoring.